The collaboration will focus on discovering novel small molecule therapies for cancer and neurodegenerative diseases, using Orionis’ Allo-Glue platform.
As part of the collaboration, CeraVe will assist The Daisy Foundation in standing up programs that recognize the importance of the care provided by nurses nationwide.
Boehringer Ingelheim, Ginkgo partner on $406M deal to address difficult-to-treat diseases